JESÚS MARÍA
BAÑALES ASURMENDI
University College London
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de University College London (11)
2023
2022
-
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
Gut, Vol. 71, Núm. 8, pp. 1669-1683
2021
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
Mapping the human genetic architecture of COVID-19
Nature, Vol. 600, Núm. 7889, pp. 472-477
-
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis
Journal of Hepatology, Vol. 74, Núm. 1, pp. 20-30
2020
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059
-
Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis
Cancers, Vol. 12, Núm. 12, pp. 1-27
2019
-
CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1865, Núm. 9, pp. 2246-2256
-
Diagnostic and prognostic biomarkers in cholangiocarcinoma
Liver International, Vol. 39, Núm. S1, pp. 108-122
-
Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma
Hepatology, Vol. 69, Núm. 2, pp. 587-603